{
    "clinical_study": {
        "@rank": "154828", 
        "arm_group": [
            {
                "arm_group_label": "canakinumab", 
                "arm_group_type": "Experimental", 
                "description": "subcutaneous injection"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "subcutaneous injection"
            }
        ], 
        "brief_summary": {
            "textblock": "ThIS study is to determine whether canakinumab is able to induce and maintain a clinically\n      meaningful reduction of disease activity in participants with HPF (Hereditary Periodic\n      Fevers) compared to placebo."
        }, 
        "brief_title": "Study of Efficacy and Safety of Canakinumab in Patients With Hereditary Periodic Fevers", 
        "completion_date": {
            "#text": "April 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Hereditary Periodic Fevers", 
        "condition_browse": {
            "mesh_term": [
                "Fever", 
                "Familial Mediterranean Fever", 
                "Amyloidosis", 
                "Hereditary Autoinflammatory Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria: - Patient's written informed consent (or parent's written informed\n        consent in case of pediatric patient) at screening - Male and female patients at least 2\n        years of age at the time of the screening visit. - Confirmed diagnosis and active flare at\n        randomization - CRP >10mg/L at randomization\n\n        Exclusion Criteria: - Use of the following therapies (within varying protocol defined\n        timeframes): Corticosteroids, anakinra, canakinumab, rilonacept, tocilizumab, TNF\n        inhibitors, abatacept, tofacitinib, rituximab, leflunomide, thalidomide, cyclosporine,\n        intravenous immunoglobulin, 6-Merceptopurine, azathioprine, cyclophosphamide, or\n        chlorambucil, any other investigational biologics - History of malignancy of any organ\n        system (other than localized basal cell carcinoma of the skin or in - situ cervical\n        cancer), treated or untreated - Significant medical diseases, including but not limited to\n        the following: a. History of organ transplantation b. Elevated liver enzymes \u22652x ULN d.\n        Increase in total bilirubin e. Serious hepatic disorder (Child-Pugh scores B or C) f.\n        Chronic Kidney Disease g. Thyroid disease h. Diagnosis of active peptic ulcer disease i.\n        Coagulopathy j. Significant CNS effects including vertigo and dizziness - Any conditions\n        or significant medical problems which immunecompromise the patient and/or places the\n        patient at unacceptable risk for immunomodulatory therapy - Live vaccinations within 3\n        months prior to the start of the trial, during the trial, and up to 3 months following the\n        last dose"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "2 Years"
        }, 
        "enrollment": {
            "#text": "180", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 7, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02059291", 
            "org_study_id": "CACZ885N2301"
        }, 
        "intervention": [
            {
                "arm_group_label": "canakinumab", 
                "description": "subcutaneous injection", 
                "intervention_name": "canakinumab", 
                "intervention_type": "Drug", 
                "other_name": "ACZ885"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "subcutaneous injection", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Antibodies, Monoclonal"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Canakinumab, interleukin-1, Hereditary Periodic Fevers, auto-inflammatory diseases", 
        "lastchanged_date": "February 20, 2014", 
        "number_of_arms": "2", 
        "official_title": "Study of Efficacy and Safety of Canakinumab in Patients With Hereditary Periodic Fevers", 
        "overall_contact": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone": "+41613241111"
        }, 
        "overall_contact_backup": {
            "last_name": "Novartis Pharmaceuticals"
        }, 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "Belgium: Federal Agency for Medicinal Products and Health Products", 
                "Canada: Health Canada", 
                "Denmark: Danish Medicines Agency", 
                "Germany: Paul-Ehrlich-Institut", 
                "Russia: Pharmacological Committee, Ministry of Health", 
                "Switzerland: Swissmedic", 
                "Turkey: Ministry of Health", 
                "United States: Food and Drug Administration", 
                "Finland: Finnish Medicines Agency", 
                "France: L'Agence nationale de s\u00e9curit\u00e9 du m\u00e9dicament et des produits de sant\u00e9 (ANSM)", 
                "Greece: National Organization of Medicines", 
                "Hungary: National Institute of Pharmacy", 
                "Ireland: Irish Medicines Board", 
                "Israel: Ministry of Health", 
                "Italy: The Italian Medicines Agency", 
                "Japan: Pharmaceuticals and Medical Devices Agency", 
                "Netherlands: Dutch Health Care Inspectorate", 
                "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "April 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To demonstrate significant reduction of disease activity with canakinumab versus placebo", 
            "measure": "Proportion of participants with resolution of initial flare at time of the randomization and absence of new flares", 
            "safety_issue": "No", 
            "time_frame": "16 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02059291"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Assessment of Physician's global assessment", 
                "measure": "Percentage of participants who achieve Physician's global assessment < 2", 
                "safety_issue": "No", 
                "time_frame": "16 weeks"
            }, 
            {
                "description": "Normalization of C-reactive protein, Serum Amyloid A", 
                "measure": "Percentage of participantswith the serologic remission", 
                "safety_issue": "No", 
                "time_frame": "16 weeks"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}